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Abstract 
Relative sparing of episodic memory is a diagnostic criterion of behavioural variant 
frontotemporal dementia (bvFTD). However, increasing evidences suggest that 
bvFTD patients can show episodic memory deficits at a similar level as Alzheimer’s 
disease (AD). Social cognition tasks have been proposed to distinguish bvFTD, but no 
study to date has explored the utility of such tasks for the diagnosis of amnestic 
bvFTD. Here, we contrasted social cognition performance of amnestic and non-
amnestic bvFTD from AD, with a subgroup having confirmed in vivo pathology 
markers. 
Ninety-six participants (38 bvFTD and 28 AD patients as well as 30 controls) 
performed the short Social-cognition and Emotional Assessment (mini-SEA). BvFTD 
patients were divided into amnestic versus non-amnestic presentation using the 
validated Free and Cued Selective Reminding Test (FCSRT) assessing episodic 
memory.  
As expected, the accuracy of the FCSRT to distinguish the overall bvFTD group from 
AD was low (69.7%) with ~50% of bvFTD patients being amnestic. By contrast, the 
diagnostic accuracy of the mini-SEA was high (87.9%). When bvFTD patients were 
split on the level of amnesia, mini-SEA diagnostic accuracy remained high (85.1%) 
for amnestic bvFTD vs. AD and increased to very high (93.9%) for non-amnestic 
bvFTD vs. AD. 
Social cognition deficits can distinguish bvFTD and AD regardless of amnesia to a 
high degree and provide a simple way to distinguish both diseases at presentation. 
These findings have clear implications for the diagnostic criteria of bvFTD. They 
suggest that the emphasis should be on social cognition deficits with episodic memory 
deficits not being a helpful diagnostic criterion in bvFTD. 
 
Key words: Alzheimer’s disease, frontotemporal dementia, episodic memory, 
neuropsychology, social-cognition, amnesia, differential diagnosis. 
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Introduction 
Relative sparing of episodic memory remains a diagnostic feature of 
behavioural variant frontotemporal dementia (bvFTD) and is heralded as the 
neuropsychological gold standard to distinguish bvFTD from Alzheimer’s disease at 
presentation.[1,2] However, increasing evidence suggest that bvFTD patients can 
show episodic memory deficits,[3] with a subgroup of bvFTD patients being impaired 
to a similar level as Alzheimer’s disease, even in biologically and pathologically 
confirmed cases.[4,5] Similarly, on a neural level, memory-related structures of the 
limbic system are found to be affected up to a similar degree as Alzheimer’s disease 
in bvFTD.[3,6-8]  
By contrast, social cognition assessments have emerged as powerful new tools 
to distinguish both diseases in a clinical setting, when CSF biomarkers or amyloid 
imaging are not available.[9-11] However, it is currently not clear whether the high 
sensitivity and specificity for social cognition deficits in bvFTD holds regardless of 
their amnestic impairment when compared to Alzheimer’s disease as previous study 
only investigated social cognition in non-amnestic bvFTD. In others words, in case of 
severe episodic memory deficits, is assessment of social cognition able to 
discriminate between the two diseases? The current study addresses this question by 
contrasting social cognition performance of biologically confirmed amnestic vs. non-
amnestic bvFTD as well as Alzheimer’s disease patients and healthy controls. We 
hypothesized that social cognition deficits can distinguish bvFTD from Alzheimer’s 
disease regardless of amnesia.  
 
Materials and methods 
Participants 
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Ninety-six subjects were selected from the database of the Memory and 
Alzheimer Institute of the Pitié-Salpêtrière Hospital from September 2005 to June 
2012. Twenty-eight typical Alzheimer’s disease patients were selected according to 
the revised NINCDS-ADRDA criteria.[1] Among them, thirteen Alzheimer’s disease 
patients underwent a lumbar puncture showing biological evidence of the Alzheimer’s 
disease pathophysiological process from their CSF biomarker profile defined by a P-
Tau/Aß42 ratio greater than 0.21.[12]  
Thirty-eight bvFTD patients met the following inclusion criteria: prominent 
changes in personality and social behavior according to the core clinical diagnostic 
criteria for probable FTD,[13] clinical progression consistent with the diagnosis of 
bvFTD (therefore excluding so-called “FTD phenocopies”), frontal/fronto-temporal 
atrophy at MRI scan and/or frontal/fronto-temporal hypoperfusion at SPECT scan and 
normal CSF biomarker profile as defined by P-Tau/Aß42 ratio lower than 0.21 when 
a lumbar puncture was performed (n=17/38, 45%). We included patients with 
memory impairment if the other core diagnostic criteria of bvFTD were present. Two 
patients had a genetic mutation (1 GRN, 1 MAPT). 
Thirty healthy controls were selected according to the following criteria: 
normal scores at the MMSE and the FAB, no depression, and no history of psychiatric 
or neurological conditions. Controls were matched to patients on age and education. 
Importantly, all patients were followed-up over at least three years. The 
clinical progression of every patient was in favour of the initial diagnosis. We did not 
include participants who presented with the following: (1) clinical or neuroimaging 
evidence of focal lesions, (2) severe cortical or subcortical vascular lesions on brain 
MRI, (3) severe depression, or (4) motor neuron disease. 
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Measurement of CSF biomarkers 
 CSF samples were collected by lumbar puncture and analyzed for total Tau, Tau 
phosphorylated at threonine 181 (P-Tau) and Aβ42 using a double-sandwich enzyme-
linked immunosorbent assay (ELISA) method (Innogenetics, Gent, Belgium). Assays 
were conducted at the Metabolic Biochemistry Department of the Pitié-Salpêtrière 
Hospital, as described elsewhere.[12] 
 
Neuropsychological assessment 
All patients underwent a neuropsychological assessment that included the 
Mini Mental State Exam (MMSE),[14] the Frontal Assessment Battery (FAB),[15] 
the Free and Cued Selective Reminding Test (FCSRT),[16] the mini-SEA,[9] 
semantic and morphologic verbal fluencies, digit spans, and a picture-naming task in 
order to identify semantic memory deficits. In addition, bvFTD patients were tested 
with the Mattis Dementia Rating Scale (MDRS) and the modified Wisconsin Card 
Sorting Task (WCST).[17,18] 
 
Assessment of episodic memory (FCSRT) 
 The FCSRT is based on a semantic cueing method that controls for effective 
encoding of the list of words and facilitates retrieval by semantic cueing.[16] 
Immediate cued recall was tested in a first phase in order to control for encoding (16 
written words presented in groups of 4x4, maximum score = 16). Then, the memory 
phase was performed in three successive recall trials. Each recall trial included (1) a 
free recall attempt consisting of spontaneous recall of as many items as possible, then 
(2) a cued recall attempt using an orally presented semantic category for items that 
were not spontaneously retrieved by the patient. The same semantic cues given in the 
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initial encoding stage were used. This provided (1) a free recall score and (2) a total 
(free + cued) recall score (/48). Then, after an interval of 30 minutes, a last recall trial 
was performed, providing (3) a delayed total recall score (/16). 
 
 
Social cognition & Emotional Assessment (mini-SEA) 
 The mini-SEA taps into social cognition and emotion disturbances. It consists 
of two subtests and provides two weighted composite scores: (1) a facial emotion 
recognition test, scored from 0 to 15, in which participants must identify the emotion 
expressed in a photograph of a face (happiness, surprise, neutral, sadness, disgust, 
anger and fear); (2) a shortened version of the Faux-Pas Recognition Test,[19] scored 
from 0 to 15, which evaluates theory of mind, where participants must detect and 
explain social faux-pas through short stories. The overall mini-SEA composite score 
is calculated by adding the two subscores, and scored from 0 to 30. More details about 
the administration procedure were presented before in a previous study.[39]   
 
Standard protocol approvals, registrations and patient consent. 
Controls were included in the INSERM RBM-05-15 study, which was 
approved by the Ethics Committee of the Pitié-Salpêtrière hospital. Participants 
provided written informed consent before participating. For all patients, the biological 
and clinical data were generated during routine clinical work-ups and were 
retrospectively extracted for the purpose of this work. According to French 
legislation, explicit informed consent was waived as patients and their relatives were 
informed that individual data might be used in retrospective clinical research studies. 
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Definition of bvFTD subgroups 
In order to test the ability of the mini-SEA to distinguish amnestic bvFTD 
patients from Alzheimer’s disease, the bvFTD group was divided in two subgroups 
based on the total recall score of the FCSRT, resulting in A-bvFTD (amnesic bvFTD; 
n=19; 50%) and nonA-bvFTD (non-amnesic bvFTD; n=19; 50%). The normative data 
of the FCSRT were employed to compare the total recall score of each patient to its 
age and educational matched normative group and, consecutively, abnormal scores 
were defined as scores below the 10th centile.[20] Data of the FCSRT for the bvFTD 
group and result of this analysis are presented in the Supplementary Material 1. 
 
Statistical analysis  
Data were analyzed using SPSS20 (SPSS Inc., Chicago, IL). Prior to any 
analysis, variables were plotted and checked for normality of distribution using the 
Shapiro-Wilk test. Parametric data were compared across the four groups (controls, 
Alzheimer’s disease, A-bvFTD, nonA-bvFTD) via ANOVA, followed by Student’s t-
test. Non-parametric data were analyzed by Kruskal-Wallis ANOVA followed by the 
Mann-Whitney test for two-by-two comparisons. Cohen’s d effect-size was computed 
for all comparisons. Correlations were analyzed using Spearman rank coefficient. 
Bonferroni’s correction for multiple measures was applied for all analyses. Logistic 
stepwise regression analysis (using the Enter method) and Area Under the Curve were 
processed in order to determine the accuracy of the mini-SEA to classify each patient 
in its correct (bvFTD or Alzheimer’s disease) group.  
 
Results 
Demographics, clinical characteristics and neuropsychological scores 
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The three groups (controls, Alzheimer’s disease, bvFTD) were not 
significantly different with regard to age, gender and educational level (Table 1). 
Patient groups did not differ on duration of disease. Not surprisingly, MMSE and 
FAB scores were significantly lower in the bvFTD and Alzheimer’s disease groups 
compared to controls (p<.10-7). No difference in the MMSE score was observed 
between bvFTD and Alzheimer’s disease, as well as for digit spans (forward and 
backward), semantic fluency and picture denomination task. FAB and morphological 
fluency scores were significantly lower in bvFTD compared to Alzheimer’s disease 
(p<.001). No difference was observed between bvFTD patients who underwent LP or 
had a genetic confirmation (n=21/38) and those who did not (n=17/38) for any 
clinical features and neuropsychological scores (Supplementary Material 2). The 
same result (ie. no difference for any features or scores) was observed between 
Alzheimer’s disease patients who underwent LP (n=13/28) and those who did not 
(n=15/28) (Supplementary Material 4). 
 Demographics, clinical characteristics and neuropsychological executive 
scores of A-bvFTD and nonA-bvFTD are presented in Table 2. There was no 
significant difference in age, gender, education, disease duration, MMSE, executive 
cognitive scores (MDRS, WCST, FAB, verbal fluency), language (picture naming), 
working memory (forward/backward digit span) between A-bvFTD and nonA-bvFTD 
patients. A-bvFTD and nonA-bvFTD were respectively 9 and 12 to have a diagnosis 
confirmation (CSF excluding Alzheimer’s disease, or genetic mutation). Within 
bvFTD subgroups (A-bvFTD and nonA-bvFTD), there was no difference on any 
demographic, clinical or cognitive measures between patients with and without LP 
(Supplementary Material 2 and 3). 
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Episodic memory scores  
At the group level, bvFTD patients had significantly higher free recall (p=.10-
4; d=0.79), total recall (p<10-4; d=0.83) and delayed total recall scores (p<10-5; 
d=0.97) than Alzheimer’s disease patients (Figure 1). bvFTD and Alzheimer’s disease 
patients did not differ on encoding score. Each FCSRT score of each patient was 
compared to its age and educational matched normative group. bvFTD patients were 
47.4% (n=18/38), 65.8% (n=25/38), 50% (n=19/38) and 42.1% (n=16/38) to have a 
score below normative scores for, respectively, encoding, free recall, total (free+cued) 
recall and delayed total recall at the FCSRT. Alzheimer’s disease patients were 35.7% 
(n=10/28, 1 missed data), 85.7% (n=24/28), 85.7% (n=24/28), 75% (n=21/28) to have 
a score below normative scores for, respectively, encoding, free recall, total 
(free+cued) recall and delayed total recall at the FCSRT (Supplementary Material 1, 
Supplementary Table 1). Binary logistic regression using the Enter method using the 
FCSRT correctly classified bvFTD or Alzheimer’s disease with 69.7% of accuracy. 
AUC for this test (bvFTD vs Alzheimer’s disease) was 0.773. ROC curve for the 
FCSRT is displayed on Figure 1. The overlap between bvFTD and AD on the FCSRT 
total recall score was 53%. 
At the subgroup level, the ANOVA showed significant difference between the 
three patient groups for all memory scores. More precisely, as expected, A-bvFTD 
patients performed similarly to Alzheimer’s disease patients for each memory scores 
(table 3, figure 2), although they had significantly lower encoding (p<.10-4; d=1.58), 
free recall (p<.10-5; d=0.88), total recall (p<.10-7; d=1.21) and delayed total recall 
(p<.10-7; d=0.87) scores than nonA-bvFTD patients. The nonA-bvFTD patients had 
higher encoding (p<.10-4; d=1.40), free recall (p<.10-6; d=1.48), total recall (p<.10-7; 
d=1.67) and delayed total recall (p<.10-7; d=1.51) than Alzheimer’s disease patients. 
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Results were similar when analyses were restricted to bvFTD who underwent LP or 
had genetic mutation and there were also no differences in the results when 
contrasting bvFTD who underwent LP or had genetic mutation and bvFTD with 
clinical diagnosis only, or when the analyses were restricted to bvFTD with clinical 
diagnosis only (Supplementary Material 2 and 3).  
 All these analyses were replicated using gender, age then duration of disease 
as covariates. No effect of these variables was observed and therefore, results did not 
change. In addition, gender effect was specifically assessed using direct comparison 
between males and females in each group and no differences were observed. 
 
Social cognition and emotional assessment 
At a group level, compared to controls, bvFTD patients had significantly 
lower scores in both the reduced Faux-pas test and the emotion recognition subtests 
(all p’s<.10-7, with respectively d=2.27 and d=2.61)  and therefore a lower total mini-
SEA total score (p<.10-7; d=3.27). Alzheimer’s disease patients had a lower 
emotions recognition score (p<.10-4; d=0.91) but showed no significant difference 
with controls on the Faux-pas test score and on the total mini-SEA score, although a 
trend was observed for the later (Figure 1; Supplementary Table 2). Compared to 
bvFTD, Alzheimer’s disease patients had higher total mini-SEA (p<10-7; d=2.41), 
Faux-pas (p<10-7; d=2.09) and emotions recognition (p<10-7; d=1.90) scores. 
Logistic regression was able to classify patients into bvFTD or Alzheimer’s disease in 
87.9% of cases when using the mini-SEA total score and in 89.2% or 76.9% in using 
either the reduced Faux-pas or the emotions recognition score. The results were 
similar when the analyses were restricted to the patients with CSF/genetic data 
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(Supplementary Material 2 and 3). The overlap between bvFTD and AD on the mini-
SEA score was inferior to 11%. 
AUC for the mini-SEA (Alzheimer’s disease vs bvFTD) was 0.949. ROC 
curve for the mini-SEA is displayed on Figure 1. 
At the subgroup level (Table 3), ANOVA showed significant differences 
between the groups. Compared to controls, A-bvFTD and nonA-bvFTD groups had 
significantly lower scores in both the Faux-pas component (all p values <.10-7; 
respectively d=2.37 and d=2.60) and the Emotion recognition component (all p values 
<.10-7; respectively d=2.71 and d=2.56) and therefore a lower total mini-SEA score 
(all p values <.10-7; respectively d=3.25 and d=3.22). Alzheimer’s disease patients 
had a lower emotions recognition score (p<.10-4; d=0.91) but showed no significant 
difference with controls on the Faux-pas test score and on the total mini-SEA score, 
although a trend was observed for the later. A-bvFTD and nonA-bvFTD patients also 
had significantly lower Faux-pas (respectively p<.10-6; d=2.10 and p<.10-6; d=2.15) 
and emotions recognition scores than Alzheimer’s disease patients (respectively 
p<.10-6; d=1.92 and p<.10-5; d=1.65), as well as a lower mini-SEA total score 
(respectively p<.10-7; d=2.40 and p<.10-7; d=2.38). A-bvFTD and nonA-bvFTD did 
not significantly differ on these measures. Results were similar when analyses were 
restricted to bvFTD who underwent LP or had genetic mutation and there were also 
no differences in the results when contrasting bvFTD who underwent LP or had 
genetic mutation and bvFTD with clinical diagnosis only, or when the analyses were 
restricted to bvFTD with clinical diagnosis only (Supplementary Material 2 and 3). 
Similarly to the analyses conducted on FCSRT scores, analyses for the mini-
SEA were replicated using gender, age then duration of disease as covariates. No 
effect of these variables was observed and therefore, results did not change. In 
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addition, gender effect was specifically assessed using direct comparison between 
males and females in each group and no differences were observed. 
 
Accuracy of the mini-SEA to distinguish A-bvFTD or nonA-bvFTD from 
Alzheimer’s disease.  
When bvFTD patients were divided on the basis of the presence of episodic 
amnesia, the mini-SEA has an accuracy of 85.1% to distinguish A-bvFTD patients 
from Alzheimer’s disease and 93.9% to distinguish nonA-bvFTD from Alzheimer’s 
disease.  
Finally, in order to confirm the discriminative power of the mini-SEA, we 
conducted logistic regression analyses using independent random samples from the 
initial dataset for mini-SEA and FCSRT (Total recall) scores. They are presented in 
the Supplementary Material and showed very similar results, therefore confirming the 
sample-based results. 
 
Correlation analyses 
Age was set as a nuisance variable in correlations analyses. In Alzheimer’s 
disease, the FAB was significantly correlated to the total mini-SEA score (R=0.60) 
and the FCSRT free recall (R=0.51). The MMSE was also correlated to the FCSRT 
encoding score (R=0.47) and the emotion recognition (R=0.47). The digit-span 
(forward) was correlated to the emotion recognition (R=0.51) and the mini-SEA 
scores (R=0.64). In bvFTD, the MMSE was significantly correlated to the FAB 
(R=0.62) and the digit-span (forward) (R=0.48). No other significant correlation was 
observed. 
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Discussion  
 Our results clearly show that social cognition can discriminate biologically 
confirmed bvFTD and Alzheimer’s disease to a high degree. More importantly, social 
cognition deficits are unrelated to the level of amnesia in bvFTD and thus may 
provide a uniquely sensitive and specific cognitive marker for the detection of the 
underlying pathology.  
 In more details, the preservation of episodic memory in bvFTD has been 
recently challenged by an increasing number of independent studies showing that 
bvFTD patients can present with similar levels of amnesia as Alzheimer’s 
disease,[4,5] with both manifesting a combination of frontally mediated and storage-
based memory impairment. Although previous studies have suggested that prefrontal 
cortex degeneration might be the greatest determinant of amnesia in bvFTD,[21,22] 
more recent evidence suggest that bvFTD patients also show severe atrophy of the 
medial temporal lobes, including the hippocampus as well as the entire Papez 
circuit.[4,6] One of the only studies that cross-correlated episodic memory 
performance with grey matter intensity in bvFTD and Alzheimer’s disease showed 
that posterior parietal and cingulate regions were implicated exclusively in 
Alzheimer’s disease while temporal poles and medial frontal regions were involved 
specifically in bvFTD.[8] Although the profile of cortical involvement in episodic 
amnesia is different in bvFTD and Alzheimer’s disease, current available episodic 
memory assessments (i.e. words-list based) may lack of power to differentiate the 
amnestic form of bvFTD from Alzheimer’s disease.[3,5] 
By contrast, during the last decade, there has been increasing evidence for the 
ability of social cognition assessment to distinguish bvFTD from other diseases and 
specifically from Alzheimer’s disease,[23] as it taps into ventral and rostral parts of 
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the medial prefrontal cortex,[24,25] which are specifically damaged in bvFTD,[26] 
even at the early stages of the disease.[27] However, the utility of social cognition 
tasks to differentiate amnestic bvFTD from Alzheimer’s disease has not been 
investigated before. Our findings show that regardless of the presence of episodic 
amnesia, the mini-SEA can distinguish bvFTD from Alzheimer’s disease to a high 
degree, with a classification power of 87.9% at group level and, more precisely, an 
accuracy of 85.1% and 93.9% to respectively distinguish A-bvFTD and nonA-bvFTD 
from Alzheimer’s disease. By comparison, the FCSRT lacked of power to distinguish 
bvFTD from Alzheimer’s disease as it was able to classified only 69.7% of patients. 
The overlap between both groups (53%) was too high to allow an accurate distinction, 
although bvFTD obtained better performances than AD. By contrast, the overlap 
between AD and bvFTD using the mini-SEA was low (11%). 
Research on social cognition benefits from the increasing recognition that 
social cognitive processes are crucial for human interactions and adequate social 
adaptation. A growing number of tests are available to assess the deficits in this 
domain, which all have different psychometric properties.[28] Theory of mind 
assessments are particularly useful for capturing the cognitive deficits related to the 
behavioral symptomatology of bvFTD,[29] but a consensus is needed amidst the 
numerous available tests. Recently, Bora and colleagues provided crucial findings by 
conducting a meta-analysis across theory of mind studies in bvFTD and Alzheimer’s 
disease in order to determine the sensitivity and specificity of theory of mind tasks 
evaluating different processes such as faux-pas recognition, sarcasm detection, false 
belief and reading the mind in the eyes.[30] Besides replicating previous findings by 
showing that theory of mind deficits could accurately differentiate bvFTD from 
Alzheimer’s disease, the results showed that faux-pas and sarcasm tests have the 
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greatest discriminatory potential between both diseases.[31] Moreover, social 
adaptation also relies on the accurate recognition of other’s emotional expressions, a 
critical process that allows adjusting one’s behavior during a social interaction.[32] 
This process is also impaired in bvFTD and relatively spared in AD during the early 
stages of the diseases.[33,34,35] This highlights the importance of assessing emotion 
recognition concurrently with theory of mind. Historically, neuropsychological testing 
of social cognition relied on long and experimental tasks, which are not always 
feasible in a clinical setting. The mini-SEA has been designed to provide a quick and 
easy way to assess theory of mind and emotional recognition through revised and 
shortened versions of the faux-pas and facial emotion recognition tests.[19,36] This 
test has been linked, in bvFTD, to grey matter degeneration and perfusion decrease in 
rostral medial prefrontal cortex,[37,38] and has been shown to accurately distinguish 
bvFTD from Alzheimer’s disease and depression.[9,39]  
Our findings have strong implications on a biomarker level. Indeed, current 
diagnosis of sporadic bvFTD remains challenging, as no biomarkers exist to diagnose 
the disease. The episodic memory problems in bvFTD further complicate the picture. 
CSF biomarkers and amyloid imaging showed robust results for identifying 
Alzheimer’s disease relative to controls or patients suffering from FTD.[40] However 
these investigations rely either on a lumbar puncture, an invasive exam for patients 
that requires a day of hospitalization, or expensive neuroimaging requiring the 
production of short-life radioisotopes which require a cyclotron and therefore cannot 
be performed outside of expert-centers. Similarly, radiological observations of 
hippocampal volumes have been proposed as a promising specific biomarker for 
Alzheimer’s disease, but recent studies challenged this finding, showing that bvFTD 
could present with a similar degree of atrophy.[4,6] Short cognitive tests, such as the 
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mini-SEA, could therefore provide a simple, inexpensive, non-invasive and efficient 
way to distinguish both diseases at presentation, when facing to a patient with an 
episodic amnesia that could be an indicator or Alzheimer’s disease or bvFTD. This 
might be in particular relevant for the detection of specific pathology (tau, TDP-43) in 
bvFTD. For example, a recent study by the Genetic Frontotemporal dementia 
Initiative (GENFI), a multi-center study on presymptomatic FTD, has shown that 
genetic predisposed tau patients (MAPT) show severe hippocampal atrophy already 
up to 10 years before diagnosis.[41] Thus, detection of memory problems in addition 
to social cognition deficits might be a potential cognitive marker for tau-bvFTD.  
On the other hand, the present results raise the question about the specificity 
of the current framework for the diagnosis of bvFTD. The International consensus 
criteria for bvFTD proposes the presence of executive deficits with relative sparing of 
memory and visuospatial functions as neuropsychological features of bvFTD,[13] 
without any reference to social cognition tests. Considering the increasing evidence of 
episodic memory impairment in bvFTD, and the diagnostic value of tests that tap into 
emotional and social abilities, it may be valuable to propose these tests as clinical 
markers for bvFTD diagnosis.  
Although these results are in accordance with previous studies about the 
clinical relevancy to use social cognition tests to discriminate bvFTD from 
Alzheimer’s disease,[23,28,30] it is important to consider that they could lack of 
power to distinguish the minority of bvFTD patients that have an Alzheimer’s disease 
underlying pathology. Because it taps into fronto-medial dysfunctions, the mini-SEA 
has shown to be impaired in those very specific cases.[42] Furthermore, social-
cognition performance could be also lower in severe Alzheimer’s disease cases, as 
both theory of mind and emotion recognition performance have been shown to 
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decrease over the course of Alzheimer’s disease as a consequence of a more general 
cognitive deterioration,[30,34] which was highlighted in this study by the correlation 
between general cognition and social-cognition performance in Alzheimer’s disease. 
However, we believe that these findings have critical implication on the clinical 
distinction of bvFTD and Alzheimer’s disease in bringing evidence that social 
cognition could accurately distinguish bvFTD from Alzheimer’s disease, regardless of 
amnesia.  
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Demographics and clinical data Alzheimer’s 
disease 
bvFTD Controls 
Nb. 28 38 30 
Mean age at test, y 70.3 (11.1) 66.6 (9.3) 67.2 (8.7) 
Education, y 11.0 (3.6) 10.9 (3.8) 10.7 (3.7) 
Disease duration, y 3.5 (2.8) 2.7 (1.8) - 
Sex, M/F 16/12 24/14 15/15 
MMSE (/30) 24.3 (2.7) † 23.4 (3.4) † 29.0 (0.9) *§ 
FAB (/18) 14.9 (2.0) †* 12.1 (3.3) †§ 17.1 (1.0) *§ 
Nb. of patients with LP 13 19 - 
Nb. of patients with genetic mutation 0 2 - 
CSF Biomarkers    
CSF Aβ42 311.2 (122.1) * 422.7 (144.1) § - 
CSF Tau 580.4 (255.3) * 241.2 (108.4) § - 
CSF P-Tau 88.1 (32.3) * 39.1 (16.3) § - 
CSF Tau / Aβ42 2.18 (0.9) * 0.84 (0.3) § - 
CSF P-Tau / Aβ42 (cut-off = 0.21) 0.32 (0.1) * 0.09 (0.04) § - 
 
Table 1 – Mean (SD) scores for Alzheimer’s disease, behavioural variant frontotemporal dementia 
(bvFTD) and control groups on demographics, general cognitive tests and clinical data. 
Abbreviations: y= years; MMSE: Mini Mental State Examination; FAB: Frontal Assessment Battery: 
LP: Lumbar Puncture; CSF: Cerebro-spinal fluid biomarquers;  
*Significant difference compared to bvFTD.  
†Significant difference compared to Controls.  
§Significant difference compared to Alzheimer’s disease.  
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Table 2 –Demographics data and Neuropsychological scores for A-bvFTD and nonA-bvFTD. 
Abbreviation: MDRS: Mattis Dementia Rating Scale; mWCST: modified Wisconsin Card Sorting 
Task; mini-SEA: abbreviated version of the Social cognition and Emotional Assessment. Mean (SD). 
 
 
 
 
  A-bvFTD nonA-bvFTD 
No. 19 19 
Mean age at test, y 66.5 (8.8) 66.6 (10.1) 
Education, y 10.4 (4.2) 11.4 (3.5) 
Disease duration, y 2.7 (1.8) 2.8 (1.9) 
Sex, M/F 11/8 13/6 
MMSE (/30) 22.5 (3.8) 24.3 (2.8) 
FAB (/18) 11.3 (3.7) 13.0 (2.6) 
 
Executive Neuropsychological scores 
MDRS (/144) 116.3 (16.3) 124.4 (11.5) 
Verbal Fluency (morphologic) 4.4 (3.5) 7.3 (4.1) 
Verbal Fluency (semantic) 9.9 (3.3) 13.4 (4.8) 
mWCST category (/6) 2.3 (1.2) 2.8 (4.9) 
mWCST perseveration errors 9.2 (7.4) 7.2 (4.3) 
mWCST attentional errors 3.4 (2.3) 3.1 (4.3) 
Picture naming (%) 94.0 (5.2) 97.0 (4.2) 
Digit span forward 4.9 (1.0) 5.7 (1.5) 
Digit span backward 3.1 (0.8) 3.6 (1.5) 
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FCSRT scores Alzheimer’s 
disease 
A-bvFTD nonA-bvFTD Controls 
Encoding (/16) 13.3 (2.4) † 11.8 (2.9) † 15.2 (0.9) § - 
Free recall (/48) 9.8 (5.7) † 11.8 (8.7) † 18.3 (5.8) § - 
Total recall (/48) 27.8 (11.3) † 30.8 (12.6) † 42.5 (5.2) § - 
Delayed total recall (/16) 7.9 (4.7) † 10.4 (4.8) † 13.9 (3.1) § - 
     
mini-SEA scores     
Total (/ 30) 24.3 (2.9) †& 16.3 (3.7) *§ 16.4 (3.7) *§ 25.8 (1.8) †& 
Faux-pas (/15) 13.0 (1.7) †& 9.2 (1.9) *§ 8.2 (2.7) *§ 13.2 (1.5) †& 
Emotion recognition (/15)  11.3 (1.7) *†& 7.0 (2.7) *§ 8.1 (2.2) *§ 12.6 (1.1) †§& 
 
Table 3 – Mean (SD) Free and Cued Selective Reminding Test (FCSRT) and mini-SEA scores for 
Alzheimer’s disease, amnestic (A-bvFTD) or non-amnestic (nonA-bvFTD) behavioural variant 
frontotemporal dementia and controls. 
*Significant difference compared to Controls.  
†Significant difference compared to nonA-bvFTD.  
§Significant difference compared to Alzheimer’s disease. 
&Significant difference compared to A-bvFTD 
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Figure 1 
 
 
 
 
Figure 2 
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Figures’ short titles 
Figure 1. Episodic memory & social cognition in bvFTD and Alzheimer’s disease. 
Figure 2. Episodic memory & social cognition in Alzheimer’s disease and in the 
amnestic and non-amnestic presentation of bvFTD. 
 
Figures’ legends 
Figure 1. Performance (percentage of correct performance) at the FCSRT and the 
mini-SEA in Alzheimer’s disease (AD) and behavioral variant frontotemporal 
dementia (bvFTD) (left graph) and ROC curve for the FCSRT and the mini-SEA for 
the diagnostic distinction between bvFTD and AD. 
 
Figure 2. Performance (percentage of correct performance) at the FCSRT and the 
mini-SEA in Alzheimer’s disease (AD) and amnestic (A-bvFTD) and non-amnestic 
(nonA-bvFTD) behavioral variant frontotemporal dementia (bvFTD). 
 
Authors’ contribution 
MB: design, clinical and experimental data acquisition, analysis and interpretation, 
and manuscript writing. 
LCDS: clinical data acquisition, interpretation and manuscript editing. 
CO: interpretation and manuscript editing. 
AG: interpretation and manuscript editing. 
MS: clinical data acquisition and manuscript editing. 
BD: clinical and experimental data acquisition and manuscript editing. 
MH: design, analysis and interpretation and manuscript writing. 
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Social cognition deficits – the key to discriminate behavioural variant 
frontotemporal dementia from Alzheimer’s disease regardless of amnesia 
Bertoux et al. 
 
Supplementary Material 1 
 
 
FCSRT scores AD bvFTD 
Encoding (/16) 
No. of patients below normative scores 
13.3 (2.4) 
36% 
13.6 (2.7) 
47.4 % 
Free recall (/48) 
No. of patients below normative scores 
9.8 (5.7) * 
85.7% 
15.2 (7.9) § 
65.8% 
Total recall (/48) 
No. of patients below normative scores 
27.8 (11.3) * 
85.7% 
36.9 (11.0) § 
50% 
Delayed total recall (/16) 
No. of patients below normative scores 
7.9 (4.7) * 
75% 
12.3 (4.3) § 
42.1% 
 
Supplementary Table 1 – Episodic memory performance of AD and bvFTD. 
Mean (SD) Free and Cued Selective Reminding Test (FCSRT) scores and percentage 
of patients that had pathological scores according to age/education normative scores, 
for Alzheimer’s disease (AD) and behavioural variant frontotemporal dementia 
(bvFTD). 
*Significant difference compared to bvFTD.  
§Significant difference compared to AD. 
 
 
 
 
mini-SEA scores AD bvFTD Controls 
Total (/ 30) 24.3 (2.9) * 16.3 (3.7) †§ 25.8 (1.8) * 
Faux-pas (/15) 13.0 (1.7) * 8.7 (2.4) †§ 13.2 (1.5) * 
Emotion recognition (/15) 11.3 (1.7) *† 7.6 (2.5) †§ 12.6 (1.1) *§ 
 
Supplementary Table 2 – Social cognition and emotional assessment (mini-SEA) 
performance of AD, bvFTD and Controls. Mean (SD) mini-SEA total and 
subscores for Alzheimer’s disease (AD), behavioural variant frontotemporal dementia 
(bvFTD) and Controls. 
*Significant difference compared to bvFTD.  
†Significant difference compared to Controls.  
§Significant difference compared to AD. 
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Supplementary Material 2 
 
Comparability between bvFTD patients with clinical diagnosis as well as CSF or 
genetic mutation and bvFTD patients with clinical diagnosis only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3 - Statistical analysis of the differences between patients 
with a clinical diagnosis of bvFTD without genetic confirmation or 
pathophysiological biomarkers excluding AD (bvFTD-CLI, n=17) and patients 
with a clinical diagnosis of bvFTD and a genetic confirmation or 
pathophysiological biomarkers excluding AD (bvFTD-CONF, n=21). 
 
 
Demographics, clinical and neuropsychological measures. 
 
For demographics, clinical and neuropsychological measures, no significant 
differences were observed between bvFTD-CLI and bvFTD-CONF. 
 
 
FCSRT. 
 
For memory measures (FCSRT), patients were divided into amnestic and non-
amnestic groups (using the same procedure as the one described in the main 
manuscript).  
 
Amnestic patients: there was no difference between amnestic bvFTD-CLI and 
amnestic bvFTD-CONF on encoding (Z=-0.702 ; p=0.497), free recall (Z=-0.860 ; 
p=0.400), total recall (Z=-1.068 ; p=.315) and delayed total recall (Z=-0.906 ; 
p=0.400).  
 
  bvFTD-CLI vs 
bvFTD-CONF 
Mean age at test, y Z=-.456; p=.651  
Education, y Z=-0.544; p=.601 
Disease duration, y Z=-1.800 p=.080 
MMSE (/30) Z=-1.374; p=.170 
FAB (/18) Z=-.230; p=.821 
 
Executive Neuropsychological scores 
MDRS (/144) Z=-.748; p=.475 
Verbal Fluency (morphologic) Z=-.464; p=.681 
Verbal Fluency (semantic) Z=-.086; p=.935 
mWCST category (/6) Z=-.875; p=.422 
mWCST perseveration errors Z=-.803; p=.451 
mWCST attentional errors Z=-.181; p=.859 
Picture naming (%) Z=-1.356; p=.183 
Digit span forward Z=-.366; p=.731 
Digit span backward Z=-.157; p=.891 
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Non-amnestic patients: there was no difference between non-amnestic bvFTD-CLI 
and non-amnestic bvFTD-CONF on encoding (Z=-0.479 ; p=0.657), free recall (Z=-
1.200 ; p=0.238), total recall (Z=-0.083 ; p=.968) and delayed total recall (Z=-
0.463 ; p=0.717).  
 
 
mini-SEA. 
 
Differences between each bvFTD amnestic subgroups were also assessed for the 
mini-SEA. 
 
Amnestic patients: There was no difference between amnestic bvFTD-CLI and 
amnestic bvFTD-CONF on the mini-SEA total score (Z=-0.163 ; p=0.905). 
 
Non-amnestic patients: There was no difference between non-amnestic bvFTD-CLI 
and non-amnestic bvFTD-CONF on the mini-SEA total score (Z=-1.569 ; p=0.129). 
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Supplementary Material 3 
Comparability between amnestic and non-amnestic bvFTD patients, all with 
clinical diagnosis, without CSF or genetic mutation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 4 - Statistical analysis of the differences between A-bvFTD 
(n=10) and nonA-bvFTD (n=7) patients, all with clinical diagnosis without 
genetic confirmation or pathophysiological biomarkers excluding AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5 - Statistical analysis of the differences between A-bvFTD 
(n=9) and nonA-bvFTD (n=12) patients, all with genetic confirmation or 
pathophysiological biomarkers excluding AD. 
  A-bvFTD vs nonA-
bvFTD 
Mean age at test, y Z=-.635; p=.536  
Education, y Z=-1.631; p=.148 
Disease duration, y Z=-1.002; p=.388 
MMSE (/30) Z=-1.718; p=.088 
FAB (/18) Z=-1.668; p=.109 
 
Executive Neuropsychological scores 
MDRS (/144) Z=-1.451; p=.181 
Verbal Fluency (morphologic) Z=-1.532; p=.181 
Verbal Fluency (semantic) Z=-1.457; p=.174 
mWCST category (/6) Z=-1.785; p=.091 
mWCST perseveration errors Z=-.757; p=.470 
mWCST attentional errors Z=-.646; p=.534 
Picture naming (%) Z=-1.664; p=.203 
Digit span forward Z=-1.549; p=.142 
Digit span backward Z=-1.521; p=.152 
  A-bvFTD vs nonA-
bvFTD 
Mean age at test, y Z=-.498; p=.651  
Education, y Z=-1.582; p=.129 
Disease duration, y Z=-.829; p=.427 
MMSE (/30) Z=.000; p=1.000 
FAB (/18) Z=-.153; p=.882 
 
Executive Neuropsychological scores 
MDRS (/144) Z=-.888; p=.384 
Verbal Fluency (morphologic) Z=-1.356; p=.182 
Verbal Fluency (semantic) Z=-1.149; p=.278 
mWCST category (/6) Z=-.704; p=.503 
mWCST perseveration errors Z=-.124; p=.904 
mWCST attentional errors Z=-.307; p=.808 
Picture naming (%) Z=-1.406; p=.143 
Digit span forward Z=-.348; p=.780 
Digit span backward Z=-.475; p=.661 
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Demographics, clinical and neuropsychological measures. 
 
For demographics, clinical and neuropsychological measures, no significant 
differences were observed between A-bvFTD and nonA-bvFTD in bvFTD-CLI only 
(Table A.4) and in bvFTD-CONF only (Table A.5). 
 
 
FCSRT. 
 
For memory measures (FCSRT), patients were divided into amnestic and non-
amnestic groups (using the same procedure as the one described in the main 
manuscript).  
 
bvFTD-CLI: there was a significant difference between amnestic bvFTD-CLI and 
non-amnestic bvFTD-CLI on encoding (Z=-2.187 ; p=0.034), free recall (Z=-1.991 ; 
p=0.049), total recall (Z=-3.849 ; p=.000001) and delayed total recall (Z=-3.801 ; 
p=0. 000001).  
 
bvFTD-CONF: there was a significant difference between amnestic bvFTD-CONF 
and non-amnestic bvFTD-CONF on encoding (Z=-2.728 ; p=0.005), free recall (Z=-
3.320 ; p=0.0005), total recall (Z=-3.420 ; p=.00001) and delayed total recall (Z=-
3.379 ; p=0.0002). 
 
 
mini-SEA. 
 
Differences between each bvFTD diagnosis subgroups were also assessed for the 
mini-SEA. 
 
bvFTD-CLI: There was no difference between amnestic bvFTD-CLI and non-
amnestic bvFTD-CLI on the mini-SEA total score (Z=-0.640 ; p=0.554). 
 
bvFTD-CONF There was no difference between non-amnestic bvFTD-CONF and 
non-amnestic bvFTD-CONF on the mini-SEA total score (Z=-0.683 ; p=0.536). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Social-cognition & Amnesia in bvFTD  
 36 
 
 
Supplementary Material 4 
Comparability between AD patients with clinical diagnosis as well as CSF and 
AD patients with clinical diagnosis only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 6 - Statistical analysis of the differences between patients 
with a clinical diagnosis of AD without pathophysiological biomarkers of AD (AD-
CLI n=15) and patients with a clinical diagnosis of AD and pathophysiological 
biomarkers of AD (AD-CONF, n=13). 
 
 
For demographics, clinical and neuropsychological measures, no significant 
differences were observed between AD-CLI and AD-CONF (Table A.6). 
 
 
FCSRT. 
 
AD-CLI vs AD-CONF: there was no significant difference between AD-CLI and AD-
CONF on encoding (Z=-.450 ; p=0.667), free recall (Z=-.905 ; p=0.373), total recall 
(Z=-.587 ; p=.581) and delayed total recall (Z=-.591 ; p=0.581).  
 
 
mini-SEA. 
 
AD-CLI vs AD-CONF: there was no significant difference between AD-CLI and AD-
CONF on the mini-SEA score (Z=-.342; p=0.755). 
 
 
 
 
 
 
 
 
  AD-CLI vs AD-
CONF 
Mean age at test, y Z=-1.906; p=.059  
Education, y Z=-.565; p=.614 
Disease duration, y Z=-.327 p=.755 
MMSE (/30) Z=-.025; p=.981 
FAB (/18) Z=-1.357; p=.198 
 
Executive Neuropsychological scores 
Verbal Fluency (morphologic) Z=-.579; p=.631 
Verbal Fluency (semantic) Z=-1.052; p=.317 
Picture naming (%) Z=-.407; p=.727 
Digit span forward Z=-1.806; p=.076 
Digit span backward Z=-1.875; p=.061 
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Supplementary Material 5 
 
Correlations analyses between mini-SEA subtests and FCSRT subscores in 
bvFTD and AD. 
 
Supplementary Table 7 - Statistical analysis of the correlations between mini-
SEA (SEA) scores (ToM, Emot) and FCSRT scores (ENC, FR, TR & DRT) in bvFTD 
patients. Corrected threshold of significance is p=0.007. FCSRT_ENC=Encoding 
score; FCSRT_FR=Free Recall score; FCSRT_TR=Total Recall score; 
FCSRT_DTR=Delayed Total Recall score; SEA=mini-Social cognition and 
emotional Assessment total score; TOM=Faux-pas test score; EMOT=Emotion 
recognition score 
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Supplementary Table 8 - Statistical analysis of the correlations between mini-
SEA (SEA) scores (ToM, Emot) and FCSRT scores (ENC, FR, TR & DRT) in AD 
patients. Corrected threshold of significance is p=0.007. FCSRT_ENC=Encoding 
score; FCSRT_FR=Free Recall score; FCSRT_TR=Total Recall score; 
FCSRT_DTR=Delayed Total Recall score; SEA=mini-Social cognition and 
emotional Assessment total score; TOM=Faux-pas test score; EMOT=Emotion 
recognition score 
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Supplementary Material 6 
 
We replicated the logistic regression analyses using independent random samples 
from the initial dataset, a method somewhat similar to jack-knife cross-validation, 
which was not directly feasible with SPSS. 
 
At first, observations were randomly selected by SPSS at a specified level (we chose 
to automatically set the selection on approx. 30%, 50% then 75% of patients), 
creating a filter variable. The logistic regression analyses were then performed again 
only through the filter variable. Importantly, the samples were randomly selected for 
each of the three comparisons (bvFTD vs AD; A-bvFTD vs AD; nonA-bvFTD vs 
AD). 
 
 
bvFTD vs AD FCSRT (Total recall) Mini-SEA (Total) 
Sample 1 – 15% of observations 60.0% 86.7% 
Sample 2 – 30% of observations 68.4% 83.3%  
Sample 3 – 50% of observations 62.2%  91.9%  
Sample 4 – 75% of observations 58.7% 91.9%  
 
 
A-bvFTD vs AD FCSRT (Total recall) Mini-SEA (Total) 
Sample 1 – 15% of observations 70.0% * 80.0% 
Sample 2 – 30% of observations 50.0% * 80.0% 
Sample 3 – 50% of observations 62.5% * 79.2% 
Sample 4 – 75% of observations 57.1% * 82.9% 
 
 
 
nonA-bvFTD vs AD FCSRT (Total recall) Mini-SEA (Total) 
Sample 1 – 15% of observations 100% * 90.0% 
Sample 2 – 30% of observations 100% * 83.3% 
Sample 3 – 50% of observations 100% * 84.2% 
Sample 4 – 75% of observations 100% * 85.7% 
 
* As both the Total recall score of the FCSRT was used to split the group into A-
bvFTD and nonA-bvFTD, there analyses are circular. 
 
Taken together, this last analysis confirm our sample-based results, showing that the 
mini-SEA is more accurate (from 83.3% to 91.9%) than the FCSRT (from 58.7% to 
68.4%) to distinguish bvFTD from AD at presentation. For the mini-SEA, similar 
results were observed when contrasting A-bvFTD (from 79.2% to 82.2%) or nonA-
bvFTD to AD (from 83.3% to 90.0%). 
 
